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OBJECTIVE—The purpose of this study was to examine the
effects of weight loss on sympathetic nervous system responsive-
ness to glucose ingestion in obese subjects with metabolic
syndrome, in whom such responses are reportedly blunted.
RESEARCH DESIGN AND METHODS—Thirty four subjects,
19 insulin resistant and 15 insulin sensitive and aged 55  1 years
(mean  SE) with BMI 31.6  0.6 kg/m
2, who fulﬁlled the Adult
Treatment Panel III criteria for metabolic syndrome participated.
Simultaneous measurements of whole-body norepinephrine spill-
over rate, calf blood ﬂow, and intra-arterial blood pressure were
made at times 0, 30, 60, 90, and 120 min postglucose (75 g). The
experiment was repeated after a 3-month hypocaloric diet with
or without an exercise program.
RESULTS—Body weight decreased by 8.1  0.9 and 8.4  1.1 kg
and resting norepinephrine spillover by 94  31 and 166  58
ng/min (all P  0.01) in insulin-resistant and insulin-sensitive
subjects, respectively. Weight loss was accompanied by a
marked increase in sympathetic responsiveness after glucose but
only in insulin-resistant subjects. In this subgroup, comparative
increases in norepinephrine spillover rates at baseline and after
weight loss averaged 3  25 versus 73  24 ng/min at 30 min
(P  0.039), 36  21 versus 115  28 ng/min at 60 min (P 
0.045), 9  21 versus 179  50 ng/min at 90 min (P  0.001), and
40  48 versus 106  39 ng/min at 120 min (P  0.24).
CONCLUSIONS—Weight loss reverses blunted sympathetic re-
sponsiveness to glucose ingestion in insulin-resistant subjects
with metabolic syndrome, which is relevant to postprandial
energy utilization and body weight homeostasis. Diabetes 58:
1126–1132, 2009
T
here is much evidence to indicate that the sym-
pathetic nervous system (SNS) is activated by
food intake and particularly by carbohydrate
ingestion (1–3). Oral glucose elicits a marked
and sustained increase in SNS activity over a 2-h period in
healthy humans, as assessed by measurements of plasma
norepinephrine concentration, by regional norepinephrine
spillover, and by direct microneurographic recordings of
muscle sympathetic nerve activity (MSNA) (1–3). At least
two mechanisms are thought to contribute to this neuro-
physiological response: the postprandial increase in
plasma insulin and the entrance of a nutrient into the
gastrointestinal tract (4). Insulin exerts its sympathoexcit-
atory effects either directly by facilitating central sympa-
thetic outﬂow or indirectly by activation of the baro-
receptor reﬂex in response to its peripheral vasodilatory
effects (5). The observation that C-peptide–negative dia-
betic patients retain a blunted MSNA responsiveness to
oral glucose, even in the absence of endogenous insulin
(6), suggests that insulin-independent factors such as
hemodynamic adjustment to splanchnic vasodilation and
gastrointestinal distension may also contribute to sympa-
thetic activation after carbohydrate ingestion (4). Post-
prandial SNS stimulation is physiologically important in
the regulation of facultative thermogenesis or the rise in
energy expenditure after dietary intake (7).
A growing body of data suggests that obesity and the
insulin-resistant state are accompanied by impaired sym-
pathetic neural responsiveness to physiological hyperinsu-
linemia, glucose ingestion, and changing energy states.
Vollenweider et al. (8) showed that in lean young subjects
MSNA increased by 94% in response to euglycemic hyper-
insulinemia, whereas in age-matched obese subjects the
increase was only 9%. MSNA responses to oral glucose are
diminished in insulin-resistant Pima Indians (9), and short-
term under- and overfeeding is accompanied by blunted
sympathetic responsiveness in obese subjects (10). The
metabolic syndrome is an increasingly prevalent multidi-
mensional risk factor for cardiovascular disease and type
2 diabetes. Several indexes of SNS activity, such as nor-
epinephrine spillover from sympathetic nerves and MSNA
at rest, are known to be increased in subjects with the
metabolic syndrome even in the absence of hypertension
(11,12). We have recently demonstrated that obese insulin-
resistant subjects with metabolic syndrome have both
blunted and delayed norepinephrine spillover and MSNA
responses to oral glucose compared with obese insulin-
sensitive subjects with metabolic syndrome (13). Sympa-
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1126 DIABETES, VOL. 58, MAY 2009thetic responsiveness related inversely to measures of
central adiposity and the insulin response and positively to
ﬁtness level (13).
Weight loss and exercise are recommended as ﬁrst-line
treatments for the metabolic syndrome, and both lifestyle
modalities are known to reduce SNS activity and improve
metabolic syndrome components (11). No study to date
has examined whether weight loss alters the dynamic
sympathetic neural response to glucose ingestion. The
aims of the present investigation were twofold: 1) to test
the hypothesis that weight loss would reverse the blunted
SNS response to glucose in obese individuals with meta-
bolic syndrome and 2) to compare the beneﬁts of weight
loss in insulin-resistant and insulin-sensitive subjects. To
accomplish these aims, we simultaneously measured
plasma glucose, insulin, leptin, whole-body norepineph-
rine kinetics, calf blood ﬂow, intra-arterial blood pressure,
and heart rate during a standard oral glucose tolerance
test (OGTT) at baseline and after a 12-week weight loss
program.
RESEARCH DESIGN AND METHODS
Nonsmoking, untreated, white subjects (21 male and 13 postmenopausal
female) aged 55  1 years (mean  SE) were studied. All subjects were
participating in the lifestyle intervention arms of an ongoing randomized
controlled trial examining the beneﬁts of dietary weight loss alone or together
with aerobic exercise on sympathetic activity. To be eligible, participants had
to have central obesity (waist circumference 102 cm in men and 88 cm in
women) and two or more metabolic syndrome parameters as per the updated
National Cholesterol Education Program Adult Treatment Panel III criteria
(14). These include elevated triglycerides (1.7 mmol/l); reduced HDL cho-
lesterol (1.03 mmol/l in men and 1.3 mmol/l in women); elevated fasting
glucose (5.6 mmol/l), and elevated blood pressure (130 mmHg systolic or
85 mmHg diastolic). Potential study subjects were initially screened by
physical examination, medical history, 12-lead electrocardiogram, blood bio-
chemistry, and lipid analyses. Subsequently, they underwent a ﬁtness assess-
ment, during which maximal oxygen consumption (VO2max) was measured
using an incremental cycle ergometry protocol (Quark b
2; Cosmed, Rome,
Italy). Body composition was determined by dual-energy X-ray absorptiom-
etry scan (GE-LUNAR Prodigy Advance PA130510; GE Medical Systems
Lunar, Madison, WI). Subjects with type 2 diabetes (fasting glucose 7 mmol/l
or receiving drug treatment for elevated glucose) or a history of secondary
hypertension, cardiovascular, cerebrovascular, renal, liver, or thyroid disease
were excluded. Written informed consent was obtained from all subjects. The
study protocol was approved by the Alfred Hospital Ethics Committee.
OGTT. Subjects attended at 0800 h, having fasted for 12 h and abstained from
caffeine for 18 h and from alcohol and strenuous exercise for 36 h. Before
attendance, they collected a 24-h urine specimen to quantify sodium intake.
Experiments were performed in a quiet room (ambient temperature 22°C)
with subjects lying in a supine position. They voided before commencement of
the experiments. A 20-G venous cannula was inserted into an antecubital vein
for infusion of tritiated norepinephrine, and an arterial cannula was placed
into the brachial artery for blood sampling. Subjects then ingested 75 g
glucose in liquid form (Glucaid; Fronine, Taren Point, NSW, Australia).
Arterial blood was sampled every 30 min over 2 h for the measurement of
glucose, insulin, and leptin concentrations. Whole-body insulin sensitivity was
calculated from OGTT parameters according to the formula of Matsuda and
DeFronzo (15). This insulin sensitivity index has been validated against the
euglycemic insulin clamp and is highly correlated with the rate of whole-body
glucose disposal during the clamp (r  0.73, P  0.0001) (15). Subjects were
stratiﬁed into insulin-sensitive and insulin-resistant groups based on cut
points of 2.1 and 2.1, respectively, which correspond to insulin areas under
the plasma concentration–time curve (AUC0–120)o f10,000 and 10,000 mU
 l
1  min
1, respectively (13).
SNS activity. Whole-body SNS activity during the OGTT was assessed by
measurement of the apparent rate of appearance of norepinephrine in arterial
plasma (“norepinephrine spillover rate”), using the radioisotope dilution
method (16). This technique involves the intravenous infusion of [
3H]norepi-
nephrine and measurement of norepinephrine-speciﬁc activity and endoge-
nous norepinephrine under steady-state conditions. The technique provides a
simultaneous estimate of norepinephrine plasma clearance. After a priming
bolus of 6 Ci of 1-[ring-2,5,6-
3H]norepinephrine (speciﬁc activity, 10–30
C/mmol; Perkin-Elmer), an infusion was commenced at 0.07 Ci/m
2 per min.
To ensure that steady-state levels of infusate were attained, baseline arterial
blood samples (time 0) were taken at least 30 min after commencement of the
infusion. Postglucose arterial samples were obtained at 30, 60, 90, and 120
min. Intra-arterial blood pressure and the electrocardiogram-derived heart
rate were continuously recorded and averaged over 15 min at time 0 and over
5 min at the other time points (PowerLab recording system, model ML
785/8SP; ADI Instruments).
Calf blood ﬂow measurements. Calf arterial blood ﬂow (milliliters per
minute per 100 ml tissue) was measured in the left leg using automated venous
occlusion plethysmography equipment (D.E. Hokansen, Bellevue, WA) as
described previously (13) and represented the average of 12 measurements at
times 0, 30, 60, 90, and 120 min.
Lifestyle interventions. After baseline testing, all subjects were prescribed
a hypocaloric diet designed to elicit a caloric deﬁcit of 600 kcal/day for a
period of 12 weeks. The diet consisted of 30% fat (9% saturated, 15%
monounsaturated, and 6% polyunsaturated), 48% carbohydrates, and 22%
protein and was based on a modiﬁed version of the Dietary Approaches to
Stop Hypertension diet (17). Subjects attended fortnightly for body weight and
blood pressure checks, and they completed regular prospective 4-day diet
records. In addition, a subset of 16 subjects also participated in an exercise-
training program during the 12 weeks. This consisted of 30–40 min of aerobic
cycling exercise, performed on alternate days at a moderate intensity of 65%
of their predetermined maximum heart rate. Compliance was monitored by
the measurement of VO2max and by exercise records. Because weight loss and
weight loss plus exercise resulted in similar lowering of whole-body norepi-
nephrine spillover rate (18), the lifestyle groups were pooled for this analysis.
Laboratory measurements. Plasma concentrations of neurochemicals were
determined by high-performance liquid chromatography with electrochemical
detection. Intra-assay coefﬁcients of variation (CVs) in our laboratory are 1.3%
for norepinephrine and 2.3% for [
3H]norepinephrine; inter-assay CVs are 3.8
and 4.5%, respectively. Arterial plasma glucose was quantiﬁed by enzymatic
methods using an Architect C18000 analyzer (Abbott Laboratories, North
Chicago, IL) and insulin and leptin were quantiﬁed by radioimmunoassay
(Linco Research, St. Charles, MO). Plasma total cholesterol, HDL cholesterol,
and triglycerides were determined by automated enzymatic methods and
plasma high-sensitivity C-reactive protein (hsCRP) by immunoturbidimetric
assay.
Statistical methods. Data are expressed as means  SE. Statistical analysis
was performed using SigmaStat (version 2.03 for Windows; SPSS). Differences
between insulin-sensitive and insulin-resistant subjects were compared by
Student’s unpaired t tests. The courses of norepinephrine kinetics and other
variables during the OGTT were analyzed by two-way repeated-measures
ANOVA, with the Holm-Sidak test for multiple pairwise comparisons. Non-
parametric data were log transformed before analyses. AUC0–120 values were
calculated by the trapezoidal rule. The ratio of the norepinephrine spillover
AUC0–120 to the insulin AUC0–120 was calculated for each subject as an index
of sympathetic responsiveness for a given increase in insulin concentration.
Associations between variables were evaluated by Pearson’s and Spearman’s
rank correlations, as appropriate. Forward stepwise regressions were carried
out with those univariate correlations for which P  0.05. Statistical signiﬁ-
cance was accepted at two-sided P  0.05.
RESULTS
Subject characteristics. Demographic and clinical data
for the whole group and two subgroups are shown in Table
1. Age, sex, and lifestyle treatment assignment did not
differ between the groups. Insulin-resistant subjects had
signiﬁcantly higher BMI, plasma leptin concentration, fast-
ing insulin, insulin AUC0–120, and homeostasis model as-
sessment of insulin resistance (HOMA-IR) and a
signiﬁcantly lower Matsuda insulin sensitivity index, com-
pared with insulin-sensitive subjects. Resting blood pres-
sure, ﬁtness level, 24-h urinary sodium excretion, arterial
norepinephrine concentration, and calculated norepineph-
rine spillover rate were similar in the two groups; how-
ever, norepinephrine plasma clearance was signiﬁcantly
greater in insulin-sensitive subjects.
Sympathetic responsiveness to glucose at baseline.
Norepinephrine kinetics during the OGTT are presented in
Fig. 1 for the whole group. At baseline, arterial norepi-
nephrine concentration and calculated norepinephrine
spillover rate increased signiﬁcantly only at 120 min.
Blunted sympathetic responsiveness was most pro-
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postglucose. At these time points, absolute change in
norepinephrine spillover averaged 3  40 versus 82  40
ng/min (P  0.07) and 40  48 versus 165  61 ng/min (P 
0.02) in insulin-resistant and insulin-sensitive subjects, re-
spectively. The ratio of norepinephrine spillover AUC0–120 to
plasma insulin AUC0–120 was signiﬁcantly greater in insu-
lin-sensitive subjects (10.6  1.5 vs. 3.6  0.41, P  0.001).
Sex did not inﬂuence sympathetic responsiveness. Plasma
leptin levels did not change during the course of the OGTT
in the whole group or in the two subgroups.
Correlation analysis showed a positive association be-
tween ﬁtness (VO2max/free fat mass [FFM]) and the in-
crease in norepinephrine spillover at 30 min (r  0.36, P 
0.04), 60 min (r  0.45, P  0.008), and 90 min (r  0.40,
P  0.02) postglucose. In contrast, the high-sensitivity
C-reactive protein (hsCRP) concentration was inversely
associated with the norepinephrine spillover response at
60 min (r  0.46, P  0.007) and 90 min (r  0.55, P 
0.001), as was fasting plasma leptin at 90 min (r  0.53,
P  0.002) and 120 min (r  0.38, P  0.03). BMI,
HOMA-IR, and fasting insulin correlated inversely with
TABLE 1
Demographic and clinical characteristics of study subjects
Whole group Insulin sensitive Insulin resistant
n 34 15 19
Sex (male/female) 21/13 11/4 10/9
Age (years) 55  15 4  15 5  1
BMI (kg/m
2) 31.6  0.6 30.3  0.7 32.7  0.9*
Waist (cm) 105.8  1.7 104.2  2.0 107.0  2.5
Total body fat mass (kg) 35.4  1.2 32.9  1.6 37.3  1.6
Triglycerides (mmol/l) 2.0  0.2 2.3  0.4 1.7  0.2
HDL cholesterol (mmol/l) 1.23  0.05 1.21  0.07 1.24  0.06
Leptin (ng/ml) 17.2  2.8 13.9  4.9 19.8  3.2*
hsCRP (mg/l) 2.5  0.3 2.1  0.4 2.8  0.5
Systolic blood pressure (mmHg) 132  3 133  5 132  4
Diastolic blood pressure (mmHg) 76  17 6  27 6  2
Heart rate (bpm) 62  16 0  26 4  2
24-h urinary sodium (mmol/day) 149  12 160  20 140  16
Fasting glucose (mmol/l) 5.6  0.1 5.4  0.1 5.7  0.2
Glucose AUC0–120 (mmol  l
1  min
1) 1160  25 1129  31 1184  33
Fasting insulin (mU/l) 16.8  1.0 12.4  0.9 20.3  1.0***
Insulin AUC0–120 (mU  l
1  min
1) 9974  731 6549  539 12,997  713***
Whole-body SI 2.49  0.19 3.33  0.25 1.75  0.09***
HOMA-IR 4.33  0.27 3.11  0.24 5.30  0.29***
VO2max/FFM (ml  min
1  kg
1) 28.7  0.9 30.4  1.8 27.3  0.9
Lifestyle intervention (WL/WL  EX) 18/16 7/8 11/8
Norepinephrine (pg/ml) 212  20 181  28 236  28
Whole-body norepinephrine spillover (ng/min) 399  42 465  77 347  41
Norepinephrine clearance (l/min) 2.0  0.1 2.6  0.2 1.6  0.1***
Data are means  SE. Insulin sensitive and insulin resistant deﬁned as insulin sensitivity index (SI) 2.1 and 2.1, respectively (15). *P 
0.05, ***P  0.001 vs. insulin-sensitive subjects by Student’s unpaired t test. WL, dietary weight loss alone; WL  EX, dietary weight loss and
aerobic exercise.
FIG. 1. Norepinephrine kinetics in response to 75 g oral glucose at baseline and after weight loss (WL) (n  34): whole-body norepinephrine
plasma spillover rate (A), arterial norepinephrine concentration (B), and norepinephrine plasma clearance (C). Values are means  SE. Data (log
transformed) were analyzed by two-way repeated-measures ANOVA, using the Holm-Sidak test for pairwise comparisons. **P < 0.01 and ***P <
0.001 versus time 0. Whole-body norepinephrine spillover rate: time effect P < 0.001; treatment effect P  0.01; time  treatment interaction P 
0.003. Arterial norepinephrine concentration: time effect P < 0.001; treatment effect P < 0.001; time  treatment interaction P  0.07.
Norepinephrine plasma clearance: no signiﬁcant time, treatment, or interaction effects. F, baseline; E, post–weight loss.
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P  0.04; r  0.34, P  0.05; and r  0.39, P  0.02,
respectively). HOMA-IR, insulin AUC0–120, and the abso-
lute change in plasma insulin concentration all correlated
inversely with norepinephrine spillover at 120 min (r 
0.33, P  0.05; r  0.35, P  0.05; and r  0.47, P 
0.007, respectively).
Effects of weight loss on sympathetic responsiveness.
At the end of the 12-week lifestyle intervention program,
the 34 subjects lost an average of 8.2  0.7 kg body weight
(range 1.8–17.5 kg) and 6.4  0.6 kg fat mass, and their
waist circumference decreased by 8.6  0.8 cm (all P 
0.001). VO2max/FFM increased from 28.7  0.9 to 30.8  1.1
ml  min
1  kg
1 (P  0.009). These changes were accom-
panied by a signiﬁcant improvement in all metabolic
syndrome components (Table 2). Resting norepinephrine
spillover rate and plasma norepinephrine decreased by 126 
31 ng/min and 66  15 pg/ml, respectively (both P  0.001),
whereas norepinephrine plasma clearance was unchanged.
The norepinephrine spillover response to glucose
increased after weight loss, being highly signiﬁcant at all
time points from 30 min onward (all P  0.001 versus
time 0) (Fig. 1). Lifestyle intervention had the greatest
effect on sympathetic responsiveness at 90 min, as the
absolute change in norepinephrine spillover rate in-
creased threefold at this time point from 36  26 ng/min
at baseline to 138  31 ng/min after weight loss (P 
0.02).
Subgroup and correlation analyses. Subgroup analysis
showed that insulin-resistant and insulin-sensitive subjects
lost similar amounts of body weight (8.1  0.9 vs. 8.4  1.1
kg), total body fat mass (6.0  0.7 vs. 6.9  1.1 kg), and trunk
fat mass (3.7  0.5 vs. 4.1  0.8 kg). Insulin AUC0–120 tended
to decrease more in insulin-resistant than in insulin-sensitive
subjects (2,913  626 vs. 1,543  489 mU  l
1  min
1, P 
0.10 between groups). Improvements in ﬁtness level and
whole-body insulin sensitivity index and the reductions in
24-h urinary sodium excretion did not differ between the
groups (Table 2).
Resting norepinephrine spillover rate decreased by 94 
31 and 166  58 ng/min (both P  0.01) in insulin-resistant
and insulin-sensitive subjects, respectively (P  0.29 be-
tween groups). These changes were accompanied by a
marked and statistically signiﬁcant increase in sympa-
thetic responsiveness postglucose but only in insulin-
resistant subjects (Fig. 2). Percent change in
norepinephrine spillover at baseline and post–weight loss
averaged 5  6 versus 36  11% at 30 min (P  0.03), 14 
6 versus 47  9% at 60 min (P  0.009), 9  6 versus 65 
10% at 90 min (P  0.001), and 20  13 versus 40  9% at
120 min (P  0.25) in this group. In contrast, absolute and
percent changes in norepinephrine spillover did not differ
at any of the time points in the insulin-sensitive subjects,
indicating that weight loss did not modify sympathetic
responsiveness in this group (Fig. 2). The ratio of the
AUC0–120 of norepinephrine spillover to the AUC0–120 of
plasma insulin increased from 3.57  0.41 to 4.96  0.94
(P  0.057) in the insulin-resistant subjects but did not
change in the insulin-sensitive group. Leptin concentra-
tions were unaltered during the OGTT in both groups.
Subgroup analyses by sex showed that weight loss re-
versed blunted sympathetic responsiveness to glucose in
both male and female participants (data not shown).
Correlation analysis (n  34) revealed inverse relation-
ships between the change in the log-norepinephrine spill-
over AUC0–120–to–insulin AUC0–120 ratio and changes in
fasting log leptin (r  0.433, P  0.02), abdominal fat
mass (r  0.38, P  0.03), and body weight (r  0.33,
P  0.06). Reductions in body weight, central adiposity,
and fasting leptin levels were associated with an increase
in the sympathetic response for a given level of plasma
insulin. In stepwise regression analysis, the change in log
fasting leptin concentration was independently associated
with the change in norepinephrine spillover AUC0–120–to
–insulin AUC0–120 ratio, accounting for 19% of the
variance.
Hemodynamic responses during OGTT. Paired calf
blood ﬂow data were available for 32 subjects. At baseline,
TABLE 2
Change in anthropometric, metabolic, and hemodynamic parameters after a 12-week lifestyle intervention
Whole group Insulin sensitive Insulin resistant
n 34 15 19
Body weight (kg) 8.2  0.7‡ 8.4  1.1‡ 8.1  0.9‡
Waist circumference (cm) 8.6  0.8‡ 9.8  1.3‡ 7.6  0.9‡
Total body fat mass (kg) 6.4  0.6‡ 6.9  1.1‡ 6.0  0.7‡
Trunk fat mass (kg) 3.9  0.4‡ 4.1  0.8‡ 3.7  0.6‡
Triglyceride (mmol/l) 0.7  0.1‡ 0.9  0.2‡ 0.6  0.2‡
HDL cholesterol (mmol/l) 0.06  0.03* 0.06  0.05 0.06  0.03
Fasting glucose (mmol/l) 0.6  0.1‡ 0.5  0.1‡ 0.7  0.1‡
Fasting insulin (mU/l) 4  1‡ 3  1* 5  1‡
Insulin AUC0–20 (mU l
1  min
1) 2,232  428‡ 1,543  489* 2,913  626†
Whole-body SI 1.11  0.29‡ 1.6  0.5‡ 0.7  0.2‡
Fasting leptin (ng/ml) 7.4  1.4‡ 5.7  2.2‡ 8.7  1.9‡
hsCRP (mg/l) 0.4  0.2* 0.5  0.3 0.4  0.3
Urinary sodium (mmol/day) 35  10† 35  17 35  12*
Systolic blood pressure (mmHg) 11  2‡ 13  3‡ 10  2‡
Diastolic blood pressure (mmHg) 4  1‡ 5  2† 3  1*
Heart rate (bpm) 4  1† 3  2 5  2†
VO2/FFM (ml  min
1  kg
1) 2.2  0.7† 2.0  0.9 2.3  1.2*
Resting calf blood ﬂow (ml  min
1  100 ml
1) 0.14  0.12 0.06  0.20 0.20  0.16
Data are means  SE. *P  0.05, †P 0.01, ‡P 0.001 vs. baseline by two-way repeated-measures ANOVA and Holm-Sidak pairwise
comparisons. Blood pressures are the average of ﬁve supine Dinamap recordings (model 1846 SX; Critikon, Tampa, FL). SI, insulin sensitivity
index.
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body norepinephrine spillover and resting calf blood ﬂow
(r  0.35, P  0.047). During the OGTT, calf blood flow
increased signiﬁcantly from 60 min onward at baseline and
after weight loss (time effect both P  0.001) but was not
inﬂuenced by weight loss (treatment effect P  0.22). This
was also the case when insulin-resistant and insulin-
sensitive subjects were analyzed separately. There were
no differences in the magnitude of calf blood ﬂow re-
sponses to glucose when analyzed by treatment or sub-
group. Change in calf blood ﬂow did not correlate with
change in norepinephrine spillover at any of the time
points.
Weight loss was associated with a signiﬁcant reduction
in arterial diastolic blood pressure at rest (by 9  2 mmHg,
n  32) and at all time points during the OGTT (treatment
effect P  0.001). At baseline, glucose ingestion was
accompanied by a lowering of diastolic blood pressure
that was signiﬁcant from 30 min onward (time effect P 
0.006). After weight loss, there were no signiﬁcant time
effects on diastolic blood pressure (treatment  time
interaction P  0.006). The same ﬁndings were conﬁrmed
in both insulin-resistant and insulin-sensitive subjects.
Resting arterial systolic blood pressure fell after weight
loss (by 9  3 mmHg, P  0.002); however, there were no
signiﬁcant glucose-related time effects at baseline or after
weight loss in the whole group or subgroups. Resting heart
rate fell after weight loss (by 4  1 bpm, P  0.001). After
glucose administration, heart rate increased signiﬁcantly
at all time points from 30 min onward at both the baseline
visit and the visit after weight loss (time effect P  0.001).
There were no differences in the heart rate response
between insulin-sensitive and insulin-resistant subjects.
DISCUSSION
It has long been recognized that energy-restricted diets
and physical training both exert sympathoinhibitory ef-
fects as well as improving the metabolic proﬁle of subjects
with metabolic syndrome (11,19). As such, these lifestyle
interventions are recommended as ﬁrst-line treatments for
the metabolic syndrome, a condition that is characterized
by sympathetic overactivity (12,20). The novel ﬁnding of
the present study is that weight loss by consumption of a
hypocaloric diet with or without exercise not only lowers
resting sympathetic drive but also reverses the blunted
sympathetic responsiveness to glucose ingestion that has
been reported in the obese state. In agreement with
previously published data (9,13,21), our study shows that
blunted stimulation of the norepinephrine appearance rate
is most pronounced in insulin-resistant subjects. In turn,
insulin-resistant subjects experienced the greatest in-
crease in sympathetic responsiveness after weight loss,
despite comparable weight loss in the insulin-sensitive
group. Correlation analysis showed that reductions in
body weight, central adiposity, and plasma leptin levels
were most strongly associated with the increase in the
SNS response for a given level of plasma insulin.
What mechanisms may underlie these changes in SNS
responsiveness? Despite increasing evidence for a patho-
physiological role of insulin-mediated sympathoexcitation,
the mechanisms and sites through which insulin increases
SNS activity remain to be fully elucidated. Circulating
insulin reaches the central nervous system via a saturable,
active transport process across the blood-brain barrier.
Insulin receptors are widely distributed in the human brain
in several distinct regions, including the hypothalamus
(mainly arcuate nucleus), cerebral cortex, and cerebellum
(22). In a series of rodent experiments, Muntzel (5) dem-
onstrated that intracerebroventricular insulin infusion
evoked acute increases in lumbar sympathetic nerve ac-
tivity, an effect that was abolished by anteroventral third
ventricle lesioning. In healthy humans, euglycemic hyper-
insulinemia in the postprandial range increases MSNA,
which is consistent with the concept that insulin stimu-
lates central sympathetic outﬂow (23). Impaired blood-to-
brain transport of insulin may be one mechanism
contributing to the blunted sympathetic responses to
glucose in obese insulin-resistant subjects. A reduced
cerebrospinal ﬂuid–to-plasma insulin ratio has recently
been reported with increasing BMI and HOMA-IR index,
suggesting that obesity in humans is characterized by a
relative central nervous system insulin deﬁcit (24). These
FIG. 2. Change in whole-body norepinephrine (NE) spillover (nanograms per minute) from time 0 in insulin-resistant (n  19) (A) and
insulin-sensitive (n  15 (B) subjects at baseline (f) and after weight loss (WL, ). *P < 0.05, **P < 0.01, and ***P < 0.001 versus baseline by
Student’s paired t test.
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which exhibit reduced brain capillary insulin binding
compared with lean rats (25). Reduced insulin delivery
into the brain has also been demonstrated in canine
models of insulin resistance, induced by high fat feeding or
dexamethasone administration (26). To date, there are
limited data on the beneﬁts of reversing central insulin
resistance by therapeutic interventions. Intranasal admin-
istration of insulin, which enables a direct delivery of
peptide to the brain without substantial absorption into
the blood stream, has been shown to acutely raise blood
pressure but not muscle sympathetic nerve activity in
healthy subjects (27).
An alternative explanation of our ﬁndings is that weight
loss may have improved insulin-induced vasodilation in
skeletal muscle, thus eliciting greater baroreﬂex-mediated
increases in SNS activity postglucose. Blunted vasodila-
tory responses to insulin have been previously reported in
obese compared with lean humans (8) and attributed to
impaired release of endothelium-derived mediators.
Weight loss alone or together with exercise improves
conduit and resistance artery endothelial function in obese
adults (19,28). In the present study, baseline calf blood
ﬂow was inversely related to whole-body norepinephrine
spillover; however, calf blood ﬂow responses to endoge-
nous insulin did not increase after weight loss. Similarly,
the increase in heart rate postglucose that purportedly
represents an insulin-mediated cardiac vagal withdrawal
and/or increased cardiac sympathetic outﬂow (29) was not
inﬂuenced by weight loss.
Leptin concentrations were not acutely altered by glu-
cose ingestion at baseline or after weight loss in either
subgroup, which concurs with a study in insulin-resistant
Japanese men (30) but not with another study conducted
in obese women, which showed an elevation in leptin at
times 30 and 60 min postglucose (31). In rodents, leptin
administration produces regional sympathetic activation,
and, conversely, sympathoadrenal stimulation inhibits lep-
tin expression and secretion from adipose tissue (32). The
inverse relationships between resting plasma leptin levels
and the norepinephrine spillover response at baseline and
between the fall in plasma leptin levels after weight loss
and the increase in plasma norepinephrine response sug-
gests that adiposity, insulin resistance, and leptin may all
modulate sympathetic responsiveness to carbohydrate
intake.
In summary, the present study demonstrates a hitherto
unrecognized beneﬁt of weight loss: the reversal of
blunted sympathetic responsiveness to glucose ingestion
in insulin-resistant subjects with metabolic syndrome. Our
data suggest that the improvement in central insulin
resistance, rather than the peripheral vasodilatory re-
sponse to insulin, mediated the increased sympathetic
response to glucose. Hypothalamic insulin signaling is
important in initiating a catabolic response, including
reduction in food intake and increase in energy expendi-
ture. Approximately one-third of the thermic effect of food
can be accounted for by the meal-induced increment in
SNS activity. Therefore, improvements in central insulin
resistance and sympathetic responsiveness to food intake
would be expected to have beneﬁcial effects on energy
expenditure and body weight homeostasis. Further inter-
vention trials using insulin-sensitizing agents are needed
to conﬁrm the role of central insulin resistance in
mediating blunted sympathetic responsiveness in meta-
bolic syndrome obesity. Intranasal insulin delivery may
offer another therapeutic avenue (33) to test whether
manipulating brain insulin levels affects SNS function in
this clinical setting.
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